Phathom Pharmaceuticals (PHAT) Non Operating Income (2018 - 2026)
Phathom Pharmaceuticals (PHAT) reported Non Operating Income of -$831000.0 for Q1 2026, up 94.62% year-over-year from -$426980.6 in Q1 2025, and up 98.64% quarter-over-quarter from -$61.1 million in Q4 2025.
Phathom Pharmaceuticals (PHAT) Non Operating Income (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Non Operating Income data on file, last reported at -$831000.0 in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$831000.0, up 94.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$77.8 million (down 157.69% YoY), and the FY2025 annual result was -$61.3 million, down 765662.5% from the prior year.
- Non Operating Income rose to -$831000.0 in Q1 2026 per PHAT's latest filing, from -$61.1 million in the prior quarter.
- Over five years, Non Operating Income peaked at $24.4 million in Q4 2023 and troughed at -$61.1 million in Q4 2025.
- A 5-year average of -$7.1 million and a median of -$831000.0 in 2026 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income jumped 27207.78% in 2023, then plunged 264666.67% in 2025.
- A 5-year view of Non Operating Income shows it stood at -$90000.0 in 2022, then jumped by 27207.78% to $24.4 million in 2023, then plunged by 99.8% to $49000.0 in 2024, then sank by 124744.9% to -$61.1 million in 2025, then surged by 98.64% to -$831000.0 in 2026.
- Business Quant data shows PHAT's Non Operating Income at -$831000.0 in Q1 2026, -$61.1 million in Q4 2025, and -$7000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -831,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -831,000.00 |
| Dec 31, 2025 | -61.08 Mn |
| Sep 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -15.89 Mn |
| Mar 31, 2025 | -15.45 Mn |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | -14.78 Mn |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -12.90 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Sep 30, 2023 | -7.58 Mn |
| Jun 30, 2023 | 3,000.00 |
| Mar 31, 2023 | -7.74 Mn |
| Dec 31, 2022 | -90,000.00 |
| Sep 30, 2022 | -8.56 Mn |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -7,000.00 |
| Dec 31, 2021 | 3.96 Mn |
| Sep 30, 2021 | -3.53 Mn |
| Jun 30, 2021 | 10,000.00 |